bioRxiv Science⌕ Search

Biology subjects

Gentleman, S.

Publications and source records attributed to Gentleman, S..

4 recordsLinked to original sources

Automatic Sample Segmentation & Detection of Parkinson's Disease Using Synthetic Staining & Deep Learning

The identification of Parkinsons Disease (PD) from post-mortem brain slices is time consuming for highly trained neuropathologists, often taking many hours per case. In this study, we demonstrate fully automatic PD detection, from single 1000um regions, from sections spanning from the dorsal motor nucleus of the vagus nerve to the frontal cortex. This is achieved via image processing and statistical methods, with improved accuracy demonstrated when using machine learning. Digitised stained brain sections were processed via a deep neural network to produce re-coloured, or synthetically stained, images which were then filtered and passed to a secondary network for classification. We demonstrate state-of-the-art PD detection (>90% accuracy on single 1000um regions), with the ability to perform binary classification on high resolution sections within minutes, in addition to demarcating regions of interest to the pathologist for manual visual verification. Executive SummaryThe identification of Parkinsons Disease (PD) from post-mortem brain slices is time consuming for highly trained neuropathologists, often taking many hours per case. Accurate classification and stratification of PD is critical for the confirmation that the brain donor suffered from PD and to maximise the potential usefulness of the brain in research studies to better understand the causes of PD and foster drug development. Parkinsons UK Brain Bank, at Imperial College London, has produced a dataset containing digitised images of brain sections immunostained for the protein alpha-synuclein (-syn), the pathological marker of PD; along with control cases from healthy donors. This dataset is much larger (over 400 cases), more consistent, and of higher quality (all have been stained with the same protocol and imaged within the same laboratory) than has been documented elsewhere in the literature; including those found in a meta-analysis study on detection of neurological disorders containing over 200 papers (Lima et al., 2022). The project team, consisting of neuroscientists and subject matter experts from: Imperial, NHS AI Lab Skunkworks, Parkinsons UK, and Polygeist have undertaken a 12 week project to examine the possibility of producing a Proof-of-Concept (PoC) tool to automatically load, enhance and ultimately classify those brain sections containing -syn. The initial focus of the project was to make a tool that could make a biomarker of PD, -syn, more visible to the pathologist; saving time in searching for the protein manually. This goal was quickly reached, producing a tool that could synthetically stain the -syn, marking regions of interest in a high-contrast bright green, making them quickly identifiable for the pathologist. Statistical analysis of the synthetically stained images showed that very few regions in the control group were stained compared to the PD group, raising the possibility that an automatic classifier could be developed, which became a stretch goal for the project. A bespoke neural network model was designed that processed the synthetically stained segments of each immunostained section and produced a binary judgement (whether a segment contains PD pathology or not). The model achieved >90% sensitivity for PD detection, much higher than is reported for neuropathologists (~60% sensitivity when searching for -syn patches across all stages, Signaevsky et al., 2022). While expert raters are still more precise (~6% better than the model), the model performed ~20% better than expert raters when considering precision and recall. The key output of the project is an open-source PoC tool that can automatically classify PD from digitised images of brain sections with accuracy that is approaching viability for real world applications. An MIT Licensed code repository has been released, containing all of the model development code, along with associated documentation, to allow others to build on the project teams work. This report summarises the scientific and engineering process undertaken through the development of the PoC tool.

pathology↗

Common signatures of differential microRNA expression in Parkinson's and Alzheimer's disease brains

BackgroundDysregulation of microRNA (miRNA)-mediated gene expression has been implicated in the pathogenesis and course of many neurodegenerative diseases including Parkinsons disease (PD). However, the functionally relevant miRNAs remain largely unknown. Previous meta-analyses on differential miRNA expression data in post-mortem PD brains have highlighted several miRNAs showing consistent and statistically significant effects. However, these meta-analyses were based on exceedingly small sample sizes. MethodsIn this study, we quantified the expression of the four most compelling PD candidate miRNAs from these meta-analyses in the superior temporal gyrus (STG) of one of the largest case-control post-mortem brain datasets available (261 samples), thereby quadruplicating previously investigated sample sizes. Furthermore, we probed for common differential miRNA expression signatures with Alzheimers disease (AD) by also analyzing these miRNAs in post-mortem STG of 190 AD patients and controls and by testing six top AD miRNAs in the PD brains. ResultsOf all ten analyzed miRNAs, PD candidate miRNA homo sapiens (hsa-) miR-132-3p showed evidence for differential expression in both PD (p=4.89E-06) and AD (p=3.20E-24), and AD miRNAs hsa-miR-132-5p (p=4.52E-06) and hsa-miR-129-5p (p=0.0379) showed evidence for differential expression in PD. Combining these novel data with previously published data substantially improved the statistical support (=3.85E-03 using Bonferroni correction) of the corresponding meta-analyses clearly and compellingly implicating these miRNAs in both PD and AD. Furthermore, hsa-miR-132-3p/-5p (but not hsa-miR-129-5p) showed association with neuropathological Braak PD staging (p=3.51E-03/p=0.0117), suggesting that these miRNAs may play a role in -synuclein aggregation beyond the early disease phase. ConclusionsOur study represents the largest independent assessment of recently highlighted candidate brain miRNAs in PD and AD post-mortem brain samples, to date. Our results implicate hsa-miR-132-3p/-5p and hsa-miR-129-5p to be differentially expressed in both PD and AD brains, potentially pinpointing shared pathogenic mechanisms across these neurodegenerative diseases.

neuroscience↗

Diverse human astrocyte and microglial transcriptional responses to Alzheimer's pathology

To better define roles that astrocytes and microglia play in Alzheimers disease (AD), we used single-nuclei RNA sequencing to comprehensively characterize transcriptomes in astrocyte and microglia nuclei isolated post mortem from neuropathologically-defined AD and control brains with a range of amyloid-beta and phospho-tau (pTau) pathology. Significant differences in glial gene expression (including AD risk genes expressed in astrocytes [CLU, MEF2C, IQCK] and microglia [APOE, MS4A6A, PILRA]) were correlated with tissue amyloid and pTau expression. Astrocytes were enriched for proteostatic, inflammatory and metal ion homeostasis pathways. Pathways for phagocytosis, proteostasis and autophagy were highly enriched in microglia and perivascular macrophages. Gene co-expression analyses revealed potential functional associations of soluble biomarkers of AD in astrocytes (CLU) and microglia (GPNMB). Our work highlights responses of both astrocytes and microglia for pathological protein clearance and inflammation, as well as glial transcriptional diversity in AD.

neuroscience↗

Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy Body diseases

Parkinsons disease (PD), Parkinsons disease with dementia (PDD) and dementia with Lewy bodies (DLB) are three clinically, genetically and neuropathologically overlapping neurodegenerative diseases collectively known as the Lewy body diseases (LBDs). A variety of molecular mechanisms have been implicated in PD pathogenesis, but the mechanisms underlying PDD and DLB remain largely unknown, a knowledge gap that presents an impediment to the discovery of disease-modifying therapies. Transcriptomic profiling can contribute to addressing this gap, but remains limited in the LBDs. Here, we applied paired bulk-tissue and single-nucleus RNA-sequencing to anterior cingulate cortex samples derived from 28 individuals, including healthy controls, PD, PDD and DLB cases (n = 7 per group), to transcriptomically profile the LBDs. Using this approach, we (i) found transcriptional alterations in multiple cell types across the LBDs; (ii) discovered evidence for widespread dysregulation of RNA splicing, particularly in PDD and DLB; (iii) identified potential splicing factors, with links to other dementia-related neurodegenerative diseases, coordinating this dysregulation; and (iv) identified transcriptomic commonalities and distinctions between the LBDs that inform understanding of the relationships between these three clinical disorders. Together, these findings have important implications for the design of RNA-targeted therapies for these diseases and highlight a potential molecular "window" of therapeutic opportunity between the initial onset of PD and subsequent development of Lewy body dementia.

neuroscience↗